X4 PHARMACEUTICALS, INC Payments to Acquire Marketable Securities
X4 PHARMACEUTICALS, INC (XFOR) reported Payments to Acquire Marketable Securities of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC payments to acquire marketable securities for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- X4 PHARMACEUTICALS, INC payments to acquire marketable securities for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- X4 PHARMACEUTICALS, INC payments to acquire marketable securities for the quarter ending 2025-12-31 was $1.90M, a 91.65% decline year-over-year.
- X4 PHARMACEUTICALS, INC payments to acquire marketable securities for the quarter ending 2025-09-30 was $44.53M, a 111.19% increase year-over-year.
- X4 PHARMACEUTICALS, INC payments to acquire marketable securities for fiscal 2025 was $63.39M, a 10.95% increase from fiscal 2024.
- X4 PHARMACEUTICALS, INC payments to acquire marketable securities for fiscal 2024 was $57.13M, a 239.62% increase from fiscal 2023.
- X4 PHARMACEUTICALS, INC payments to acquire marketable securities for fiscal 2023 was $16.82M.
- X4 PHARMACEUTICALS, INC payments to acquire marketable securities for fiscal 2022 was $0.00.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $1.90M derived: sum of 3 quarters · filed 2026-08-06 | $46.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 | $1.90M derived: sum of 2 quarters · filed 2026-05-06 | $46.44M derived: sum of 3 quarters · filed 2026-05-06 | $51.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $46.44M derived: sum of 2 quarters · filed 2026-03-17 | $51.50M derived: sum of 3 quarters · filed 2026-08-06 | $63.39M 10-K · filed 2026-03-17 |
| 2025-09-30 | $44.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $49.60M derived: sum of 2 quarters · filed 2026-08-06 | $61.49M 10-Q · filed 2025-11-05 | $84.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $5.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $16.95M 10-Q · filed 2026-08-06 | $39.73M derived: sum of 3 quarters · filed 2026-08-06 | $60.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $11.89M 10-Q · filed 2026-05-06 | $34.67M derived: sum of 2 quarters · filed 2026-05-06 | $55.76M derived: sum of 3 quarters · filed 2026-05-06 | $58.76M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $22.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $43.87M derived: sum of 2 quarters · filed 2026-03-17 | $46.87M derived: sum of 3 quarters · filed 2026-03-17 | $57.13M 10-K · filed 2026-03-17 |
| 2024-09-30 | $21.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $24.09M derived: sum of 2 quarters · filed 2025-11-05 | $34.35M 10-Q · filed 2025-11-05 | $40.15M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $13.27M 10-Q · filed 2025-08-08 | $19.07M derived: sum of 3 quarters · filed 2026-03-17 | $25.21M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $10.26M 10-Q · filed 2025-05-01 | $16.06M derived: sum of 2 quarters · filed 2026-03-17 | $22.21M derived: sum of 3 quarters · filed 2026-03-17 | $27.09M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | $5.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $11.95M derived: sum of 2 quarters · filed 2026-03-17 | $16.82M derived: sum of 3 quarters · filed 2026-03-17 | $16.82M 10-K · filed 2026-03-17 |
| 2023-09-30 | $6.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $11.03M derived: sum of 2 quarters · filed 2024-11-13 | $11.03M 10-Q · filed 2024-11-13 | $11.03M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-06-30 | $4.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $4.88M 10-Q · filed 2024-08-08 | $4.88M derived: sum of 3 quarters · filed 2025-03-26 | $4.88M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 | $0.00 derived: sum of 2 quarters · filed 2025-03-26 | $0.00 derived: sum of 3 quarters · filed 2025-03-26 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $0.00 derived: sum of 2 quarters · filed 2025-03-26 | $0.00 10-K · filed 2025-03-26 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-10 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |